Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Marta Ubezio et al.|Journal of Clinical Oncology|2023Cited by 109
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Olivier Nibourel, Caterina Gregorio et al.|Journal of Clinical Oncology|2024Cited by 39
A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes: a multicentre, observational cohort studyGiulia Maggioni, Uwe Platzbecker, Matteo Bersanelli et al.|The Lancet Haematology|2022Cited by 34
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)Cristina Astrid Tentori, Najla H. Al Ali, Caterina Gregorio et al.|Blood|2023Cited by 5
Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic SyndromesElisabetta Sauta, Matteo Giovanni Della Porta, Marie Robin et al.|Blood|2022Cited by 4